Experts back tamoxifen for breast cancer prevention
Executive officer Kay Francis said the MOGA had been lobbying the TGA and the PBAC and was planning to work with a pharmaceutical sponsor of the drug, which is genericised, to try to get an extended indication approved. She said the issue was a priority for the organisation.
The UK’s National Institute for Health and Clinical Excellence (NICE) published a draft position paper on familial breast cancer last month.
It recommended that tamoxifen or raloxifene be offered for five years to postmenopausal women at high risk of breast cancer, unless they have a history of thromboembolic disease or endometrial cancer.
Cancer Australia has a similar recommendation which states potentially high-risk women should consider the use of tamoxifen or raloxifene.
Raloxifene is TGA-approved for the prevention of breast cancer in high-risk women, but not PBS listed for this.
Clinical oncologist and director of